about
Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguatQuality of life in patients with chronic thromboembolic pulmonary hypertensionThe molecular targets of approved treatments for pulmonary arterial hypertensionExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSInterfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity.Cyclic nucleotide signalling in kidney fibrosis.An Update on Pulmonary Arterial Hypertension.Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.Single-particle EM reveals the higher-order domain architecture of soluble guanylate cyclase.Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance.Riociguat for the treatment of pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension: a safety evaluation.Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans.The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
P2860
Q26746202-CEB2CBC2-616D-409F-95A2-B3FB67CB04AFQ26748611-0B571DCE-0B46-4121-A522-ED9C85BDF70BQ26798308-025C2BE6-98C2-45F0-9786-40C1C7CCF11DQ27021649-670ACC18-BF63-4F49-BA46-A981C6E6E1CAQ27682500-8F355078-923D-495D-8524-D6652F5C78CBQ35138860-E8DE3433-482F-4505-8056-5DB33454D374Q35564936-7DC0C039-98C9-4F07-AE70-52B996979137Q36734217-DB3570FC-32C9-407F-8EB1-728E6FAC4AD3Q37612777-FBCE131B-7F98-40E8-840C-8E4207315D5AQ38199072-98343BD0-8AA0-49FC-BFB1-A8556442DD33Q38645382-A00C4BE6-8FE3-421E-9CE0-F26F3210B8CBQ38983098-7BBF29E5-40C5-47B5-A510-657DD72C2626Q41143611-B7350EA5-6527-4FC9-AC21-D1B164655BCEQ41225554-383DDA3B-0865-4EFF-A3E9-FD6FB0541C92Q42244904-6F64B3E7-2FAC-4DBC-82DB-34C0A8393CFDQ42787506-57D092F6-B26A-433F-9230-168CEFF986FBQ43119916-3AB5B8EE-F4E3-48DB-8702-33AB4B3921ADQ52670776-457D81A8-FBD6-40E8-8796-716553C3DB6C
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Riociguat: first global approval.
@en
type
label
Riociguat: first global approval.
@en
prefLabel
Riociguat: first global approval.
@en
P2860
P1433
P1476
Riociguat: first global approval.
@en
P2093
Daniel Conole
P2860
P2888
P304
P356
10.1007/S40265-013-0149-5
P577
2013-11-01T00:00:00Z
P5875
P6179
1019891121